This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Universitè Catholique De Louvain, Université Libre De Bruxelles. Active years: 2015.
Company Filing History:
1 out of 100 
1 out of 99 
Years Active: 2015
Title: The Innovative Contributions of Nicolas Vandelaer
Introduction
Nicolas Vandelaer is a notable inventor based in Bossut-Gottechain, Belgium. He has made significant contributions to the field of anti-cancer research through his innovative work on phenazine derivatives. His research focuses on developing compounds that can serve as effective anti-angiogenic and anti-tumor agents.
Latest Patents
Vandelaer holds a patent for "Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents." This patent includes novel phenazine derivatives that have shown potential in combating cancer. The compounds disclosed in this patent can be utilized as anti-angiogenic and/or anti-tumor agents, highlighting their importance in medical research.
Career Highlights
Throughout his career, Vandelaer has worked with prestigious institutions such as Université Catholique de Louvain and Université Libre de Bruxelles. His work in these institutions has allowed him to collaborate with leading researchers and contribute to groundbreaking studies in the field of cancer treatment.
Collaborations
Some of his notable coworkers include Olivier Feron and Olivier Riant. Their collaborative efforts have further advanced the research and development of anti-cancer agents.
Conclusion
Nicolas Vandelaer's innovative work and patent contributions have made a significant impact in the field of anti-cancer research. His dedication to developing effective treatments showcases the importance of innovation in medicine.